← Back to Screener
Mirum Pharmaceuticals, Inc. Common Stock (MIRM)
Price$95.71
Favorite Metrics
Price vs S&P 500 (26W)25.97%
Price vs S&P 500 (4W)1.17%
Market Capitalization$5.91B
All Metrics
P/CF (Annual)105.87x
Book Value / Share (Quarterly)$6.06
P/TBV (Annual)75.93x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)89.13%
Cash Flow / Share (Quarterly)$1.06
Price vs S&P 500 (YTD)19.86%
Gross Margin (TTM)80.77%
Net Profit Margin (TTM)-4.48%
EPS (TTM)$-0.48
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-0.48
EPS (Annual)$-0.47
ROI (Annual)-3.74%
Gross Margin (Annual)80.77%
Net Profit Margin (5Y Avg)-146.63%
Cash / Share (Quarterly)$7.39
Revenue Growth QoQ (YoY)49.81%
ROA (Last FY)-2.77%
Revenue Growth TTM (YoY)54.74%
EBITD / Share (TTM)$0.09
ROE (5Y Avg)-55.51%
Operating Margin (TTM)-4.25%
Cash Flow / Share (Annual)$1.06
P/B Ratio18.78x
P/B Ratio (Quarterly)12.97x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)11.36x
Net Interest Coverage (TTM)-11.89x
ROA (TTM)-3.07%
EV / EBITDA (TTM)1322.52x
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)2.67x
Quick Ratio (Quarterly)2.46x
3-Month Avg Trading Volume0.85M
52-Week Price Return152.77%
EV / Free Cash Flow (Annual)107.95x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.04
P/S Ratio (Annual)11.34x
Asset Turnover (Annual)0.62x
52-Week High$109.28
Operating Margin (5Y Avg)-125.44%
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)32.91%
26-Week Price Return34.71%
Quick Ratio (Annual)2.46x
13-Week Price Return8.05%
Total Debt / Equity (Annual)0.98x
Current Ratio (Quarterly)2.67x
Enterprise Value$5,923.575
Asset Turnover (TTM)0.69x
Book Value / Share Growth (5Y)0.98%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)4.24x
Pretax Margin (Annual)-4.11%
Cash / Share (Annual)$7.39
3-Month Return Std Dev47.02%
Gross Margin (5Y Avg)81.06%
Net Income / Employee (TTM)$-0
ROE (Last FY)-7.42%
Net Interest Coverage (Annual)-11.89x
EPS Basic Excl Extra (Annual)$-0.47
P/FCF (TTM)103.92x
Receivables Turnover (TTM)5.17x
EV / Free Cash Flow (TTM)107.95x
Total Debt / Equity (Quarterly)0.98x
EPS Incl Extra (TTM)$-0.48
Receivables Turnover (Annual)5.17x
ROI (TTM)-4.01%
P/S Ratio (TTM)11.34x
Pretax Margin (5Y Avg)-148.01%
Revenue / Share (Annual)$10.39
Tangible BV / Share (Annual)$1.04
Price vs S&P 500 (52W)117.68%
Year-to-Date Return24.00%
5-Day Price Return1.51%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)-21.62%
Net Profit Margin (Annual)-4.48%
Month-to-Date Return6.03%
Cash Flow / Share (TTM)$-4.10
EBITD / Share (Annual)$0.09
Operating Margin (Annual)-4.25%
LT Debt / Equity (Annual)0.98x
P/CF (TTM)105.87x
ROI (5Y Avg)-43.02%
LT Debt / Equity (Quarterly)0.98x
EPS Basic Excl Extra (TTM)$-0.48
P/TBV (Quarterly)75.93x
P/B Ratio (Annual)12.97x
Inventory Turnover (TTM)4.28x
Pretax Margin (TTM)-4.11%
Book Value / Share (Annual)$6.06
Price vs S&P 500 (13W)5.19%
Beta0.54x
P/FCF (Annual)107.71x
Revenue / Share (TTM)$10.12
ROE (TTM)-8.53%
52-Week Low$37.83
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.29
4.29
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MIRMMirum Pharmaceuticals, Inc. Common Stock | 11.34x | 54.74% | 80.77% | — | $95.71 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Mirum Pharmaceuticals is a biopharmaceutical company developing therapies for rare and orphan liver diseases. The company markets Livmarli, an FDA-approved bile acid transporter inhibitor for cholestatic pruritus in Alagille syndrome patients. Mirum's pipeline includes maralixibat for pediatric cholestatic liver diseases and volixibat for adult patients with cholestatic conditions.